IDH1 and glioblastoma: IDH1 inactivation with shRNAs or GSK864 (an IDH1 inhibitor) decreases GBM cell growth, promotes a more differentiated tumor cell state, increases apoptosis in response to receptor tyrosine kinase inhibitors, and prolongs the survival of patient-derived xenografts mice.